EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...
The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...
At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...
A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...
UK: A recent systematic review published in Clinical Rheumatology has investigated the potential of botulinum toxin (BTX) as ...
Internal medicine and rheumatology specialist Siobhan Deshauer, MD, goes over the visual physical signs that a patient might have diabetes ... treat it with a steroid injection to decrease ...
Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial ...
Rising incidences of eye-related conditions - such as glaucoma, macular degeneration, diabetic retinopathy ... allergic reactions, visual disturbances, and stinging, burning, or itching.
I nearly passed out and/or puked walking from one room to the other, and I had a headache with visual abnormalities for more than ... Though frightened, I agreed to a nerve block injection in my spine ...
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.